Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 11/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | BUB1 | O43683 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29525031 | 1.00 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2BRD4MAPTNPSR1 | |
| SCHEMBL8237233 | 0.96 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2BRD4MAPTNPSR1 | |
| SCHEMBL29605666 | 0.86 | KDM4E (0.41) | ALDH1A1KDM4EGAA | |
| SCHEMBL783668 | 0.86 | KDM4E (0.41) | ALDH1A1KDM4EGAA | |
| SCHEMBL23027524 | 0.84 | BRD4 (0.40) | ALDH1A1SMN1; SMN2BRD4MAPTNPSR1 | |
| SCHEMBL6686475 | 0.84 | BRD4 (0.42) | ALDH1A1SMN1; SMN2BRD4MAPTMEN1 | |
| SCHEMBL7101996 | 0.84 | BRD4 (0.40) | ALDH1A1SMN1; SMN2BRD4MAPTNPSR1 | |
| SCHEMBL24542960 | 0.84 | BRD4 (0.42) | ALDH1A1SMN1; SMN2BRD4MAPTMEN1 | |
| SCHEMBL19584901 | 0.84 | KDM4E (0.38) | ALDH1A1SMN1; SMN2BRD4MAPTHSD17B10 | |
| SCHEMBL14430372 | 0.80 | KDM4E (0.59) | ALDH1A1BRD4MAPTNPSR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3983385-B1 | NAPHTHOQUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS | PTC THERAPEUTICS INC (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-3983385-B1 | NAPHTHOQUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS | PTC THERAPEUTICS INC (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230002324-A1 | NAPHTHOQUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS | PTC THERAPEUTICS, INC. | 2023-01-05 | — | — | US | disclosed |
| US-20230002324-A1 | NAPHTHOQUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS | PTC THERAPEUTICS, INC. | 2023-01-05 | — | — | US | disclosed |
| EP-3983385-A1 | NAPHTHOQUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS | PTC Therapeutics, Inc. (US) | 2022-04-20 | — | — | EP | disclosed |
| WO-2020252414-A1 | NAPHTHOQUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS | PTC THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020252414-A1 | NAPHTHOQUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS | PTC THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| US-8569521-B2 | Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569521-B2 | Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-10-29 | — | — | US | disclosed |
| EP-1976843-B1 | CARBOCYCLIC AND HETEROCYCLIC ARYLSULFONES AS GAMMA SECRETASE INHIBITORS | MERCK SHARP & DOHME (US) | 2013-09-04 | — | — | EP | disclosed |
| WO-2007084595-A2 | CARBOCYCLIC AND HETEROCYCLIC ARYLSULFONES AS GAMMA SECRETASE INHIBITORS | SCHERING CORPORATION (US) | 2007-07-26 | — | — | WO | disclosed |
| EP-1701942-A1 | NON-NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2006-09-20 | — | — | EP | disclosed |
| US-20060167055-A1 | Non-nucleoside reverse transcriptase inhibitors | MEDIVIR AB (SE) | 2006-07-27 | — | — | US | disclosed |
| WO-2005066131-A1 | NON-NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2005-07-21 | — | — | WO | disclosed |
| EP-1534276-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2005-06-01 | — | — | EP | disclosed |
| EP-1423368-A1 | UREA AND THIOUREA DERIVATIVES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2004-06-02 | — | — | EP | disclosed |
| WO-2004021969-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2004-03-18 | — | — | WO | disclosed |
| US-6610714-B2 | HIV viricides | MEDIVIR AB (SE) | 2003-08-26 | — | — | US | disclosed |
| US-20030092743-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2003-05-15 | — | — | US | disclosed |
| WO-2003020705-A1 | UREA AND THIOUREA DERIVATIVES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2003-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002324-A1 | NAPHTHOQUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS | NFE2L2, AIFM2, GPX4 | ALDH1A1 899/4885SMN1; SMN2 340/4885BRD4 2280/4885 |
| US-20030092743-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | SUB1, HCFC1, CCR1 | ALDH1A1 848/4885SMN1; SMN2 3265/4885BRD4 1476/4885 |
| US-20060167055-A1 | Non-nucleoside reverse transcriptase inhibitors | POLR2H, POLR2E, POLR1E | ALDH1A1 2705/4885SMN1; SMN2 2895/4885BRD4 691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.